Here's Why You Should Invest in Immunotherapy Companies

Immunotherapy may be the future of fighting cancer and companies are racing to capitalize on that. We spoke with the CEO of the Damon Runyon Cancer Research Foundation to find out why.
Publish date:

Companies like Gilead Sciences (GILD) - Get Report , Merck (MRK) - Get Report , Bristol-Myers Squibb (BMY) - Get Report , and Amgen (AMGN) - Get Report , which is in Jim Cramer's AAP Portfolio, are all investing in immunotherapy.

Immunotherapy is a treatment that uses certain parts of a person's immune system to fight diseases such as cancer, by stimulating their own immune system to work harder or smarter to attack cancer cells or by giving you immune system components, such as man-made immune system proteins, according to the American Cancer Society.

"It is one of the most exciting parts of science today," says Dr. Yung Lie, the newly appointed CEO of the Damon Runyon Cancer Research Foundation, an organization that provides today's best young scientists with funding to pursue innovative cancer research.

And many of these young-guns are making huge strides in immunotherapy.  

Cancer has touched every household in some shape or form.  Imagine a day where we would no longer have to worry about it.  Immunotherapy may get us closer to that dream.